Publication Date: 2022-05-31
Practice Area: Patent Litigation
Industry: Pharmaceuticals
Court: U.S. District Court of Delaware
Judge: District Judge Connolly
Attorneys: For plaintiff: Douglas E. McCann, Gregory R. Booker, Robert M. Oakes, Nitika G. Fiorella, Kelly A. Del Dotto, Fish & Richardson P.C., Wilmington, DE; Elizabeth M. Flanagan, Michael J. Kane, Ryan V. Petty, Fish & Richardson P.C., Minneapolis, MN; W. Chad Shear, K. Nicole Williams, Fish & Richardson P.C., San Diego, CA; John M. Farrell, Fish & Richardson P.C., Redwood City, CA; Caitlin M. Dean, Fish & Richardson P.C., New York, NY; Laura E. Powell, Fish & Richardson P.C., Washington, DC; Jason Leonard, Vincent Li, McDermott Will & Emory, New York, NY; Lisa M. Ferri, Manuel J. Velez, Mayer Brown LLP, New York, NY for plaintiffs.
for defendant: Dominick T. Gattuso, Heyman Enerio Gattuso & Hirzel LLP, Wilmington, DE; Nathan R. Hoeschen, Shaw Keller LLP, Wilmington, DE; Charles B. Klein, Jovial Wong, Claire A. Fundakowski, Winston & Strawn LLP, Washington, DC; Alison M. King, Winston & Strawn LLP, Chicago, IL for defendant.
Case Number: D69833
Patent infringement claims arising from manufacture of pharmaceutical generic product failed where abbreviated new drug application expressly excluded use of form of active ingredient that was protected by patent claims, and where plaintiffs failed to submit evidence showing that any amount of patent-protected claim would be generated by the manufacturing process.